CD86 and neoplasm: The tdRT→αPD-1 induced migratory CD86/CD40/MHC II/CCR7 +DC-3 population also exhibited relatively high expression of Batf3, the canonical transcription factor driving differentiation of type I conventional dendritic cells (cDC1s), cross-presenting DCs that are required within the tumor-draining lymph node during anticancer host response to immunotherapy10,37.